1. Home
  2. MLYS vs CYH Comparison

MLYS vs CYH Comparison

Compare MLYS & CYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • CYH
  • Stock Information
  • Founded
  • MLYS 2019
  • CYH 1985
  • Country
  • MLYS United States
  • CYH United States
  • Employees
  • MLYS N/A
  • CYH N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • CYH Hospital/Nursing Management
  • Sector
  • MLYS Health Care
  • CYH Health Care
  • Exchange
  • MLYS Nasdaq
  • CYH Nasdaq
  • Market Cap
  • MLYS 890.6M
  • CYH 397.9M
  • IPO Year
  • MLYS 2023
  • CYH 1991
  • Fundamental
  • Price
  • MLYS $36.21
  • CYH $2.94
  • Analyst Decision
  • MLYS Strong Buy
  • CYH Hold
  • Analyst Count
  • MLYS 6
  • CYH 8
  • Target Price
  • MLYS $42.60
  • CYH $3.57
  • AVG Volume (30 Days)
  • MLYS 2.6M
  • CYH 1.5M
  • Earning Date
  • MLYS 11-10-2025
  • CYH 10-22-2025
  • Dividend Yield
  • MLYS N/A
  • CYH N/A
  • EPS Growth
  • MLYS N/A
  • CYH N/A
  • EPS
  • MLYS N/A
  • CYH N/A
  • Revenue
  • MLYS N/A
  • CYH $12,647,000,000.00
  • Revenue This Year
  • MLYS N/A
  • CYH N/A
  • Revenue Next Year
  • MLYS N/A
  • CYH $2.46
  • P/E Ratio
  • MLYS N/A
  • CYH N/A
  • Revenue Growth
  • MLYS N/A
  • CYH 0.81
  • 52 Week Low
  • MLYS $8.24
  • CYH $2.24
  • 52 Week High
  • MLYS $39.20
  • CYH $6.29
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 82.25
  • CYH 54.75
  • Support Level
  • MLYS $35.00
  • CYH $2.86
  • Resistance Level
  • MLYS $39.20
  • CYH $3.04
  • Average True Range (ATR)
  • MLYS 2.65
  • CYH 0.11
  • MACD
  • MLYS 1.31
  • CYH 0.03
  • Stochastic Oscillator
  • MLYS 87.88
  • CYH 70.83

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About CYH Community Health Systems Inc.

Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.

Share on Social Networks: